Author: Manas Mishra
-
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
By Manas Mishra and Bhanvi Satija (Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the drugmaker to growth. Viehbacher was hired in November to put Biogen back on a growth path after a series of…
-

Biogen announces job cuts, turns focus to Alzheimer’s drug launch
By Manas Mishra and Mariam Sunny (Reuters) -Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or 11% of its workforce, in a fresh round of cost-cutting as it looks to the launch of a new Alzheimer’s drug to help it return to growth. The company said its costs are elevated compared…
-

J&J expects inflation, China COVID hit to carry into 2023
By Bhanvi Satija and Manas Mishra (Reuters) – Johnson & Johnson on Tuesday said it sees the impact from high inflation carrying into 2023 and expects China’s major COVID-19 outbreak to dent sales at its medical devices unit in the first half of the year. Inflation has hurt demand for consumer health products and driven…
-
J&J looks at job cuts despite weathering inflation impact
By Manas Mishra and Michael Erman (Reuters) -Johnson & Johnson on Tuesday posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar. J&J Chief Financial Officer Joseph Wolk said the…
-

Amazon builds healthcare muscle with $3.49 billion One Medical deal
By Manas Mishra and Jeffrey Dastin (Reuters) -Amazon.com Inc on Thursday agreed to buy primary care provider One Medical for $3.49 billion, expanding the e-commerce giant’s virtual care presence and adding some brick-and-mortar doctors’ offices to its healthcare arsenal. The all-cash deal heralds a dramatic expansion of Amazon’s healthcare ambitions, having piloted virtual care visits…
-
Biogen leans on new Alzheimer’s drug to calm investor worries
By Manas Mishra (Reuters) -Biogen Inc on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer’s disease drug being developed with Eisai Co Ltd and promising to draw lessons from the setbacks to its treatment Aduhelm. The new drug, lecanemab, is crucial for the growth of the drugmaker as it…
-
J&J’s cancer drug sales help weather hit from stronger dollar
By Manas Mishra (Reuters) -Johnson & Johnson on Tuesday reported quarterly results that beat analysts’ estimates on strong demand for cancer drug Darzalex and its COVID-19 vaccine, even as the company cut its full-year adjusted profit forecast due to a stronger dollar. J&J joins other major U.S. multinationals with sizeable international operations, including Microsoft Corp…
-
Moderna sees higher COVID vaccine sales later this year
By Manas Mishra (Reuters) -Moderna Inc on Wednesday forecast higher vaccine sales for the second half of the year than in the first six months, as it expects the virus that causes COVID-19 to follow a more seasonal pattern requiring booster shots in the fall. The U.S. vaccine maker is developing a potential next generation…
-
J&J suspends sales forecast for COVID vaccine, cuts profit view
By Manas Mishra (Reuters) -Johnson & Johnson on Tuesday cut its full-year profit expectation and said it could no longer provide a forecast for sales of its COVID-19 vaccine because of demand uncertainty as well as surplus supply of other shots. The company had earlier predicted as much as $3.5 billion in sales from the…
-
Pfizer’s COVID product sales to top $50 billion this year, investors want more
By Manas Mishra and Michael Erman (Reuters) -Pfizer Inc said on Tuesday it expects 2022 sales of its COVID-19 vaccine and antiviral pill to top $54 billion, but that fell short of lofty Wall Street estimates and its shares fell nearly 5%. Although Pfizer raised its forecast for the vaccine, developed with Germany’s BioNTech SE,…





